Form 4: Guardant Health Director Files Future Share Sale Under 10b5-1 Plan

Myrtle S. Potter, a Director at Guardant Health, Inc., has filed a Form 4 indicating a planned sale of 26 shares of common stock on July 17, 2025, under a Rule 10b5-1 trading plan.

Summary

• Myrtle S. Potter, a Director of Guardant Health, Inc. (GH), reported a planned transaction for the disposition of shares.
• The transaction involves the sale of 26 shares of Common Stock.
• The planned transaction date is July 17, 2025.
• The shares are to be sold at a price of $48.2 per share.
• Following this planned transaction, Myrtle S. Potter will beneficially own 18,196 shares of Common Stock.
• The transaction is being made pursuant to a Rule 10b5-1(c) contract, instruction, or written plan.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While it is a director selling shares, it is a very small number (26 shares) and is explicitly stated to be part of a pre-arranged Rule 10b5-1 plan, which typically signals a scheduled financial event rather than a negative outlook on the company.

Positives

• The transaction is conducted under a Rule 10b5-1 plan, which indicates a pre-scheduled sale and not an opportunistic one, potentially reducing concerns about insider sentiment.

Negatives

• A director is planning to dispose of shares, which reduces insider ownership, though the number of shares is very small.

Future Outlook

The filing indicates a pre-planned future transaction by a director, scheduled for July 17, 2025, under a Rule 10b5-1 trading plan. This suggests a scheduled disposition of shares rather than an immediate change in outlook.

Industry Context

This Form 4 filing reports a routine insider transaction for Guardant Health, Inc., a company operating in the precision oncology and liquid biopsy industry. Such transactions are common for corporate directors and executives for personal financial planning, and this specific filing does not provide broader industry context or trends.

Comparison to Industry Standards

• This Form 4 filing details a standard insider transaction (sale of shares by a director) under a Rule 10b5-1 plan. This type of pre-arranged trading plan is a common practice among executives and directors across various industries, including biotechnology and healthcare, to manage personal holdings while complying with insider trading regulations.
• The small number of shares involved (26 shares) is not significant enough to draw direct comparisons to major industry-wide transactions or large-scale divestitures by executives in comparable companies like Exact Sciences (EXAS) or Illumina (ILMN).

Corporate Governance

Stakeholder Impact

• Shareholders: The planned sale of a small number of shares by a director slightly reduces insider ownership, but due to the small quantity and pre-planned nature, the impact on overall shareholder confidence is likely minimal.

Next Steps

• The planned disposition of 26 shares of common stock by Myrtle S. Potter is scheduled to occur on July 17, 2025.

Key Dates

Recommendation

Keywords

Guardant Health, GH, Form 4, Insider Trading, Director Sale, 10b5-1 Plan, Share Disposition, Myrtle S. Potter, SEC Filing